Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 34.04% is in line with its 5-year average of 31.73%, near the high end of its 5-year range (22.35%–36.93%).
1.27% below its 12-month average of 34.48%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 33.23%.
EBITDA MARGIN
34.04%
EBITDA MARGIN AVG TTM
34.48%
EBITDA MARGIN AVG 3Y
32.71%
EBITDA MARGIN AVG 5Y
31.73%
EBITDA MARGIN AVG 10Y
27.17%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.27%
CURRENT VS 3Y AVG
+4.08%
CURRENT VS 5Y AVG
+7.27%
CURRENT VS 10Y AVG
+25.30%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
IRadimed Corporation
Market Cap
$1.08B
EBITDA Margin
34.04%
TTM Avg
34.48%
3Y Avg
32.71%
5Y Avg
31.73%
Market Cap
$1.09B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
EBITDA Margin
-20.99%
TTM Avg
-14.27%
3Y Avg
-11.56%
5Y Avg
-5.13%
Market Cap
$1.10B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
EBITDA Margin
-15.54%
TTM Avg
-15.54%
3Y Avg
-2.35%
5Y Avg
5.20%
Market Cap
$1.11B
EBITDA Margin
-5.96%
TTM Avg
-8.24%
3Y Avg
-13.85%
5Y Avg
-8.28%
Market Cap
$1.05B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$1.13B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IRadimed Corporation (IRMD) | $1.08B | 34.04% | 34.48% | 32.71% | 31.73% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.09B | -20.99% | -14.27% | -11.56% | -5.13% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | N/A | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | -15.54% | -15.54% | -2.35% | 5.20% |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | -5.96% | -8.24% | -13.85% | -8.28% |
| Replimune Group, Inc. (REPL)vs › | $1.11B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 3.96% | -13.21% | -146.19% | -104.68% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 21.12% | 16.04% | 11.58% | 9.26% |
Gross Margin
75.9%
EBITDA Margin
34.0%
Operating Margin
31.9%
Net Margin
26.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 33.23% |
| 2026-03-31 | 35.00% |
| 2025-12-31 | 33.97% |
| 2025-09-30 | 34.04% |
| 2025-06-30 | 36.16% |
| 2025-03-31 | 28.83% |
| 2024-12-31 | 30.92% |
| 2024-09-30 | 32.67% |
| 2024-06-30 | 32.50% |
| 2024-03-31 | 28.27% |
| 2023-12-31 | 30.74% |
| 2023-09-30 | 36.93% |
| 2023-06-30 | 31.93% |
| 2023-03-31 | 27.07% |
| 2022-09-30 | 34.07% |
| 2022-06-30 | 36.64% |
| 2022-03-31 | 28.50% |
| 2021-12-31 | 29.45% |
| 2021-09-30 | 31.42% |
| 2021-06-30 | 22.35% |
| 2021-03-31 | 22.86% |
| 2020-12-31 | 11.58% |
| 2020-09-30 | 14.49% |
| 2020-06-30 | -38.34% |
| 2020-03-31 | 12.47% |
| 2019-12-31 | 23.14% |
| 2019-09-30 | 28.18% |
| 2019-06-30 | 28.85% |
| 2019-03-31 | 22.53% |
| 2018-12-31 | 24.62% |
| 2018-09-30 | 19.21% |
| 2018-06-30 | 28.17% |
| 2018-03-31 | 21.31% |
| 2017-12-31 | 19.95% |
| 2017-09-30 | 17.01% |
| 2017-06-30 | 8.01% |
| 2017-03-31 | -2.99% |
| 2016-12-31 | 26.20% |
| 2016-09-30 | 34.60% |
| 2016-06-30 | 34.47% |
| 2016-03-31 | 39.51% |
| 2015-12-31 | 38.78% |
| 2015-09-30 | 39.79% |
| 2015-06-30 | 36.12% |
| 2015-03-31 | 33.12% |
| 2014-12-31 | 7.67% |
| 2014-09-30 | 11.84% |
| 2014-06-30 | 34.97% |
| 2014-03-31 | 23.75% |
| 2013-12-31 | 22.10% |
| 2013-09-30 | 15.67% |
| 2013-06-30 | 29.29% |
| 2013-03-31 | 36.56% |
